// App-Quantinova.ai

PB/CO05 : A Low Dose Heparin Protocol Is Associated with Improved Duration of Arterial Line Patency in Critically Ill COVID-19 Patients

Researchers

Presenter

  • L. Maurer

Principal Investigators

  • C. Luckhurst

  • A. Hamidi

  • K. Newman

  • M. Barra

  • M. El Hechi

  • A. Mokhtari

  • K. Breen

  • L. Lux

  • L. Prout

  • J. Lee

  • E. Bittner

  • D. Chang

  • H. Kaafarani

  • R. Roberts

  • R. Rosovsky

Medical Centers

  • Massachusetts General Hospital, Department of Surgery, Boston, United States

  • Massachusetts General Hospital, Department of Surgery, Boston, United States

  • Massachusetts General Hospital, Division of Trauma, Emergency Surgery, and Surgical Critical Care, Boston, United States

  • Massachusetts General Hospital, Department of Surgery, Boston, United States

  • Massachusetts General Hospital, Department of Surgery, Boston, United States

  • Massachusetts General Hospital, Department of Anesthesia, Critical Care and Pain Medicine, Boston, United States

  • Massachusetts General Hospital, Codman Center for Clinical Effectiveness in Surgery, Boston, United States

  • Massachusetts General Hospital, Department of Hematology & Oncology, Boston, United States

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Infectious Diseases (ID)

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

Disease

  • Venous thrombosis

  • Coronavirus disease

Biomarkers

  • N/A

Drug/Treatment

  • Heparin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved